MONONINE will be discontinued in 2021. You will soon need to consider another treatment option.
At CSL Behring, we're committed to providing treatment and support services that make a meaningful difference in the lives of people with bleeding disorders. That's why we developed IDELVION®, Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP), a next-generation therapy indicated for: on-demand, prophylaxis, and perioperative treatment to manage bleeding episodes for hemophilia B.
IDELVION resolves bleeds quickly, often in a single dose
In the IDELVION trial, adults and adolescents averaged 0 spontaneous and 0 joint bleeds per year when dosed every 7 or 14 days*
IDELVION has multiple dosing schedules, including 14-day prophylactic dosing, to meet varying needs†